Announced
Completed
Financials
Tags
Minority
Completed
Acquisition
Domestic
Friendly
Biotechnology
Private Equity
Venture Capital
United States
Private
biotechnology company
Synopsis
Casdin Capital, a private equity firm, led a $28m Series B round in Xcell Biosciences, a biotechnology company, with the participation from Dynamk Capital, Formic Ventures, Labcorp, HBM Genomics and Viking Global Investors. “This new financing is an important validation of our successful track record and unique position in supporting immunotherapy researchers with innovative technology platforms focused on improving the performance of cell and gene therapies," Brian S. Feth, Xcell Co-founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.